title: Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
abstract: The objectives of the analysis were to develop and verify a venetoclax physiologically based pharmacokinetic (PBPK) model to predict the effects of cytochrome P450 3A (CYP3A) inhibitors and inducers on the PK of venetoclax and inform dosing recommendations. A minimal PBPK model was developed based on prior in vitro and in vivo clinical data using a "middle-out" approach. The PBPK model was independently verified against clinical studies of the strong CYP3A inhibitor ketoconazole, the strong CYP3A inducer, multiple-dose rifampin, and the steady-state venetoclax PK in chronic lymphocytic leukemia (CLL) subjects by comparing predicted to observed ratios of the venetoclax maximum concentration (CmaxR) and area under the curve from time 0 to infinity (AUC∞R) from these studies. The verified PBPK model was then used to simulate the effects of different CYP3A inhibitors and inducers on the venetoclax PK. Comparison of the PBPK model predicted to the observed PK parameters indicated good agreement. Verification of the PBPK model demonstrated that the ratios of the predicted:observed CmaxR and AUC∞R of venetoclax were within 0.8- to 1.25-fold range for strong CYP3A inhibitors and inducers. Model simulations indicated no effect of weak CYP3A inhibitors or inducers on Cmaxor AUC∞, while both moderate and strong CYP3A inducers were estimated to decrease venetoclax exposure. Moderate and strong CYP3A inhibitors were estimated to increase venetoclax AUC∞, by 100% to 390% and 480% to 680%, respectively. The recommended venetoclax dose reductions of at least 50% and 75% when coadministered with moderate and strong CYP3A inhibitors, respectively, maintain venetoclax exposures between therapeutic and maximally administered safe doses.
authors.affiliation: AbbVie, Inc, North Chicago, IL, USA.
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Freise
authors.affiliation: AbbVie, Inc, North Chicago, IL, USA.
authors.forename: Mohamad
authors.initials: M
authors.lastname: Shebley
authors.affiliation: AbbVie, Inc, North Chicago, IL, USA.
authors.forename: Ahmed Hamed
authors.initials: AH
authors.lastname: Salem
mesh_terms: D000970:Antineoplastic Agents / Q000097:blood / Q000493:pharmacokinetics*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000097:blood / Q000493:pharmacokinetics*; D065701:Cytochrome P-450 CYP3A Inducers / Q000494:pharmacology*; D065692:Cytochrome P-450 CYP3A Inhibitors / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008954:Models, Biological; D013449:Sulfonamides / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D065701:Cytochrome P-450 CYP3A Inducers; D065692:Cytochrome P-450 CYP3A Inhibitors; D013449:Sulfonamides; C579720:venetoclax
keywords: ABT-199/GDC-0199; BCL-2; CYP3A; PBPK; drug-drug interaction; venetoclax